Free Trial
Don't Let the A.I. Investing Revolution Pass You By!Last Chance - Get 30 Days Free

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Should You Buy?

Written by MarketBeat
September 25, 2025
Regencell Bioscience logo with Manufacturing background

Key Points

  • Regencell Bioscience's stock price gapped up to $15.48 before trading at $14.46 with a volume of 75,969 shares.
  • Several large investors acquired new stakes in Regencell Bioscience in the second quarter, including Geode Capital Management, which raised its holdings significantly by 5,637.5%.
  • Regencell focuses on the research and commercialization of Traditional Chinese medicine for treating neurocognitive disorders, primarily ADHD and autism.
  • Five stocks we like better than Regencell Bioscience.

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report)'s stock price gapped up before the market opened on Thursday . The stock had previously closed at $14.58, but opened at $15.48. Regencell Bioscience shares last traded at $14.46, with a volume of 75,969 shares traded.

Regencell Bioscience Trading Up 2.6%

The business's 50 day moving average price is $13.84.

Hedge Funds Weigh In On Regencell Bioscience

Several large investors have recently bought and sold shares of the business. Greenfield Savings Bank acquired a new stake in Regencell Bioscience in the second quarter worth $187,000. Y Intercept Hong Kong Ltd acquired a new stake in Regencell Bioscience in the second quarter worth $222,000. BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience in the second quarter worth $768,000. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience in the second quarter worth $1,701,000. Finally, Geode Capital Management LLC raised its holdings in Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company's stock worth $6,664,000 after purchasing an additional 384,250 shares during the period. 0.13% of the stock is currently owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

(Get Free Report)

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Regencell Bioscience Right Now?

Before you consider Regencell Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regencell Bioscience wasn't on the list.

While Regencell Bioscience currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.